← Leaderboards
David H Johnson
Vanderbilt University
$5,849,161
Attributed
$5,849,161
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $889.5K · FY2005–11$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
Funding mix
By agency
NIH$5,849,161 · 4
By mechanism
U10$4,094,708 · 1
P50$1,080,372 · 2
T32$674,081 · 1
Top collaborators
No co-investigators on record.
Most similar at Vanderbilt University
Same institution · by research overlap
- John A Oates$7,158,915
- Matthew Douglas Breyer$9,196,649
- Raymond Nelson Dubois$22,706,669
- Richard M Breyer$8,994,550
- Kenneth L Brigham$6,521,337
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical TrialsNeoplasm /Cancer ChemotherapyNeoplasm /Cancer GeneticsCancer PatientTumorReportingMalignant NeoplasmsPathologyLeukemiaFigs - DietaryProgramsAngiogenesisResearch PersonnelChemotherapyClinical ResearchAntineoplasticsFundingGrantGrowthPrincipal InvestigatorHuman Therapy EvaluationNeoplasm /Cancer Radiation TherapyNeoplasm /Cancer Surgery
Grant awards (21)
EICOSANOID PATHWAY TARGETS IN LUNG CANCER$207,943
P50 · FY2011 · CA · contact PI
EICOSANOID PATHWAY TARGETS IN LUNG CANCER$219,591
P50 · FY2010 · CA · contact PI
Eastern Cooperative Oncology Group$362,155
U10 · FY2009 · CA · contact PI
Vanderbilt Training Program in Academic Cancer Research$258,839
T32 · FY2009 · CA · contact PI
EICOSANOID PATHWAY TARGETS IN LUNG CANCER$220,309
P50 · FY2009 · CA · contact PI
Eastern Cooperative Oncology Group$390,865
U10 · FY2008 · CA · contact PI
Vanderbilt Training Program in Academic Cancer Research$277,614
T32 · FY2008 · CA · contact PI
EICOSANOID PATHWAY TARGETS IN LUNG CANCER$221,036
P50 · FY2008 · CA · contact PI
Eastern Cooperative Oncology Group$390,329
U10 · FY2007 · CA · contact PI
EICOSANOID PATHWAY TARGETS IN LUNG CANCER$211,493
P50 · FY2007 · CA · contact PI
Vanderbilt Training Program in Academic Cancer Research$137,628
T32 · FY2007 · CA · contact PI
Eastern Cooperative Oncology Group$387,793
U10 · FY2006 · CA · contact PI
Eastern Cooperative Oncology Group$426,296
U10 · FY2005 · CA
Eastern Cooperative Oncology Group$436,068
U10 · FY2004 · CA
EASTERN COOPERATIVE ONCOLOGY GROUP$430,690
U10 · FY2003 · CA
EASTERN COOPERATIVE ONCOLOGY GROUP$435,349
U10 · FY2002 · CA
ROLE OF COX2 IN LUNG CANCER ANGIOGENESIS AND METASTASIS$0
P50 · FY2002 · CA
EASTERN COOPERATIVE ONCOLOGY GROUP$422,042
U10 · FY2001 · CA
ROLE OF COX2 IN LUNG CANCER ANGIOGENESIS AND METASTASIS$0
P50 · FY2001 · CA
ROLE OF COX2 IN LUNG CANCER ANGIOGENESIS AND METASTASIS$0
P50 · FY2001 · CA
EASTERN COOPERATIVE ONCOLOGY GROUP$413,121
U10 · FY2000 · CA